APVO (Aptevo Therapeutics) Total Operating Expense: $26.67 Mil (TTM As of Mar. 2026)


APVO Aptevo Therapeutics Inc APVO
29 GF Score
Price $4.55
! 1 Warning Sign
View Full Analysis

What is Aptevo Therapeutics Total Operating Expense?

Aptevo Therapeutics APVO 29 Total Operating Expense is $26.67 Mil as of Mar. 2026. GuruFocus rates APVO with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

Aptevo Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was $6.84 Mil. Aptevo Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $26.67 Mil.

Aptevo Therapeutics Total Operating Expense Related Terms

Aptevo Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Aptevo Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aptevo Therapeutics Total Operating Expense Chart

Aptevo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.69 31.76 28.88 24.60 26.31

Aptevo Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.48 6.23 7.61 6.00 6.84
APVO
29GF Score
Aptevo Therapeutics Inc APVO
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aptevo Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $26.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $26.67 Mil mean?
Aptevo Therapeutics (APVO) has a Total Operating Expense of $26.67 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Aptevo Therapeutics and its competitors.
Is Aptevo Therapeutics' Total Operating Expense too high?
Aptevo Therapeutics' current Total Operating Expense is $26.67 Mil. Overall, Aptevo Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aptevo Therapeutics' Total Operating Expense compare to ENVB and ADIL?
Aptevo Therapeutics' Total Operating Expense of $26.67 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Aptevo Therapeutics and its competitors. Aptevo Therapeutics's current Total Operating Expense is $26.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptevo Therapeutics stock overvalued right now?
Aptevo Therapeutics (APVO) has a current Total Operating Expense of $26.67 Mil. The current Total Operating Expense is $26.67 Mil. Aptevo Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Aptevo Therapeutics (APVO), the current Total Operating Expense is $26.67 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aptevo Therapeutics Business Description

Address 2401 4th Avenue, Suite 1050, Seattle, WA, USA, 98121
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
29GF Score

Get the complete analysis for APVO

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.55
Price